Vistagen's Fasedienol Fails to Meet Primary Endpoint in Late-Stage Social Anxiety Disorder Study

Vistagen's stock is plunging 79.53% to $0.89 after the company announced that its Phase 3 study of intranasal fasedienol for social anxiety disorder did not achieve its primary endpoint. The trial failed to demonstrate a statistically significant improvement in anxiety symptoms during a simulated public speaking challenge. The favorable safety data of fasedienol were consistent with previous clinical trials. Vistagen implemented cash preservation measures to enhance operational efficiency and provide a cash runway into 2027.